More in the News
‘It’s beyond unethical’: Opaque conflicts of interest permeate prescription drug benefits
A largely hidden flow of money between major consulting conglomerates and PBMs compromises the firms’ ability to choose prescription drug benefits for employers.
Cheaper Competition For Humira Is Hitting The Market, But Savings Will Depend On Your Insurance
Patients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July.
Sanders, Cassidy reach deal to increase access to generic prescription drugs, reform PBMs
Sens. Bernie Sanders, I-Vermont, and Bill Cassidy, R-Louisiana, reached a deal on new legislation that aims to increase access to generic drugs and impose transparency measures on pharmacy middlemen.
Cigna Is Giving Customers a Clearer View on Drug Pricing After Scrutiny
Cigna Group is offering clients a clearer view of how much they pay for drugs through its prescription plans, as the industry responds to rising Washington scrutiny and competition from smaller rivals touting greater transparency.
Senate Finance Committee Urges PBMs To Make Big Changes
Senators and witnesses at today's Senate Finance Committee on PBMs took aim at PBMs for their role in what they say keeps drug prices high for consumers and for the Medicare program.
Pharmacy orgs commend Senate intro of ‘Drug Pricing Transparency in Medicaid Act’
The National Association of Chain Drug Stores and the National Community Pharmacists Association are lauding the introduction of S. 1038, the Drug Pricing Transparency in Medicaid Act, introduced by U.S. Sens. Peter Welch (D-Vt.) and Roger Marshall (R-Kan.).
Some seniors could start paying less for certain drugs whose prices rose faster than inflation
Starting next month, some Medicare beneficiaries will pay less out of pocket for 27 prescription drugs whose prices rose faster than inflation late last year, the Department of Health and Human Services said Wednesday.
Congress Investigates How Pharma Middlemen Affect Drug Prices
House Republicans have launched an investigation into the companies that manage drug benefits, dialing up the scrutiny of the middlemen who play an important role in how much medicines cost.
The administration's next crack at lower drug prices
The Biden administration unveiled three drug payment programs Tuesday aimed at helping reduce patients' out-of-pocket costs, including one that would potentially lower Medicare payments for promising treatments approved by the FDA before clinical trials are complete.
Your Money or Your Life: Patient on $50,000-a-Week Cancer Drug Fears Leaving Behind Huge Medical Debt
After several rounds of treatment for a rare eye cancer — weekly drug infusions that could cost nearly $50,000 each — Paul Davis learned Medicare had abruptly stopped paying the bills.